+33 (0) 7 86 84 25 12. contact@jolt-capital.com

Ben Delhey, a renowned specialist in diabetes devices, will become a Boydsense Supervisory Board Member starting mid-June, and Prof. Pierre Gourdy (Toulouse University Hospital) will conduct a new clinical trial on a cohort of patients with type-2 diabetes, to enhance and validate the accuracy of Boydsense’s patented breath analyzer technology.

Ben Delhey

Ben Delhey has more than 15 years of senior management experience in the Healthcare industry. He has been working within leading diabetes Medtech and Pharma companies such as LifeScan, Ascencia and Sanofi.

Ben Delhey is a specialist in the launch of pharmaceutical devices. During his career in Sales and Marketing, he has launched more than 10 diabetes devices and software as medical devices which are distributed in more than 25 countries in the world. These major devices are world famous brands such as OneTouch® Vita®, MyStar® from Sanofi and Mhealth Software, My Dose Coach®.

“I am very excited to join the BOYDSense team. We are starting a new era in terms of technologies applied to diabetes. The last few years have been really interesting with the release of brand-new innovations. The BOYDSense device will drastically improve the way patients with diabetes will measure their blood glucose level. This is great news for patients with diabetes, because this innovation will greatly facilitate their daily life and allow them to monitor their glucose levels in a more gentle way.” commented Ben Delhey

Anton Kittelberger, Chairman of the Supervisory Board of BOYDSense, added : “Ben is the perfect addition to our team. He will bring us his huge experience in terms of diabetes, acces to the market and launching of medical devices. We are very confident because Ben has already done all these missions for Sanofi, Bayer or Johnson & Johnson. We are really looking forward to working together on our next succes.”

Prof. Pierre Gourdy

The University Hospital (CHU) of Toulouse and BOYDSense entered into an agreement to perform a clinical study to enhance and validate on a cohort of 100 people with type 2 diabetes the accuracy of the non-invasive glucose monitoring device developed by Alpha MOS’ subsidiary BOYDSense.

This is the second clinical study ordered by BOYDSense. The first one, performed at the University Hospital Coventry & Warwickshire on a cohort of 112 people has shown that BOYDSense’s patented breath analyzer technology has the potential to meet regulatory guidelines for accuracy. The goal of the second study is to test and validate the performances of the algorithms developed based on the results of the first study.

As far as next steps are concerned, BOYDSense expects to receive soon the approval of the Institutional review board (Comité de Protection des Personnes) and to start the study in the third quarter of 2021.

This is a very important step for the validation of BOYDSense technology and for people with diabetes. Founded in 2015, BOYDSense (www.boydsense.com) developed a non-invasive monitoring technology that uses molecular patterns in exhaled breath to calculate blood glucose values. Its first device is a small-form-factor device for personal use. Once commercially available, it will be affordable, will not require consumables, will have a smartphone companion app, and will provide a painless user experience for people having to monitor their metabolism.

“I am convinced that the development of this innovative method of non-invasive glucose monitoring would represent a significant breakthrough expected by a large number of people living with diabetes,” said Professor Gourdy, diabetologist at CHU Toulouse in charge of the clinical study.

Bruno Thuillier, founder of BOYDSense, commented that “We are very happy to cooperate with the University Hospital (CHU) of Toulouse. They have great expertise in testing medical devices and are experts in diabetes. Moreover, it is also very effective to have our R&D and the Clinical Research Organization both based in Toulouse.”

About University Hospital (CHU) Toulouse. CHU is a major hospital in France. In the field of diabetes clinical research, the CHU contributes actively to the progress of clinical and pharmaceutical science. It has the support of Innov’Pôle Santé which aims to accelerate technological and organizational innovation for the benefit of innovative health companies.

For more information: www.chu-toulouse.fr
Mathilde Ratineaud – tél. : 05 61 77 86 75 – mobile : 06 09 64 27 52

Marie Charrière-Lemahieu – tél. : 05 61 77 83 49 – mobile : 06 10 85 51 10 Contact Innov’Pôle Santé: +33 5.61.77.72.08

About Alpha MOS and Boydsense

Alpha MOS is the world’s leading manufacturer of electronic nose, tongue and eye for industrial use. Founded in 1993, Alpha MOS is specialized in Volatile Organic Compounds (VOCs) analysis and the digitization of smell, taste and vision. Located in France, in China and in the United States, the company manages over 1000 installs worldwide.

Boydsense is a wholly owned subsidiary of Alpha MOS.

For more information: https://www.alpha-mos.com/

Media contact

AlphaMOS: +33562475380